Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Veraflox
2. 195532-12-8
3. Pradofloxacin [inn]
4. 6o0t5e048i
5. 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
6. 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
7. Pudofloxacin
8. Unii-6o0t5e048i
9. Pradofloxacin [mi]
10. Schembl150884
11. Chembl1256815
12. Dtxsid60173229
13. Pradofloxacin [green Book]
14. Ex-a5917
15. Zinc3827732
16. Db11453
17. Pradofloxacin [ema Epar Veterinary]
18. A937065
19. Q15679498
20. 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-octahydro-6h-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
21. 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
22. 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3quinolinecarboxylic Acid
| Molecular Weight | 396.4 g/mol |
|---|---|
| Molecular Formula | C21H21FN4O3 |
| XLogP3 | 0.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 3 |
| Exact Mass | 396.15976871 g/mol |
| Monoisotopic Mass | 396.15976871 g/mol |
| Topological Polar Surface Area | 96.7 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 803 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
* Dogs:
Treatment of:
- wound infections caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius);
- superficial and deep pyoderma caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius);
- acute urinary-tract infections caused by susceptible strains of Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius);
- as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by susceptible strains of anaerobic organisms, for example Porphyromonas spp. and Prevotella spp.
* Cats:
Treatment of acute infections of the upper respiratory tract caused by susceptible strains of Pasteurella multocida, Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius).
Dogs: , Infections of the skin and soft tissues, i. e. superficial and deep pyoderma and wound infections caused by Gram-positive organisms, typically Staphylococcus spp. and Streptococcus spp. , and Gram-negative organisms such as Escherichia coli, Pseudomonas spp. and Proteus spp. , Infections of the urinary tract caused by Gram-negative bacteria such as enterobacteriaceae, e. g. Escherichia coli, Enterobacter spp. , Klebsiella spp. and Proteus spp. , Pseudomonas spp. , and Gram-positive organisms, typically Staphylococcus spp. , Infections of the gingiva and periodontal tissues caused by anaerobic organisms, for example Porphyromonas spp. , Prevotella spp. ; Fusobacterium spp. , Eikenella spp. and capnophilic bacteria such as Capnocytophaga spp. , , Cats: , Infections of the respiratory tract caused by Gram-negative organisms such as Pasteurella spp. , Escherichia coli and Pseudomonas spp. , and Gram-positive organisms such as Streptococcus spp. and Staphylococcus spp. ,
QJ01MA97
QJ01MA
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Pradofloxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pradofloxacin, including repackagers and relabelers. The FDA regulates Pradofloxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pradofloxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Pradofloxacin supplier is an individual or a company that provides Pradofloxacin active pharmaceutical ingredient (API) or Pradofloxacin finished formulations upon request. The Pradofloxacin suppliers may include Pradofloxacin API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pradofloxacin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pradofloxacin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pradofloxacin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pradofloxacin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pradofloxacin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pradofloxacin suppliers with NDC on PharmaCompass.
Pradofloxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pradofloxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pradofloxacin GMP manufacturer or Pradofloxacin GMP API supplier for your needs.
A Pradofloxacin CoA (Certificate of Analysis) is a formal document that attests to Pradofloxacin's compliance with Pradofloxacin specifications and serves as a tool for batch-level quality control.
Pradofloxacin CoA mostly includes findings from lab analyses of a specific batch. For each Pradofloxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pradofloxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Pradofloxacin EP), Pradofloxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pradofloxacin USP).
LOOKING FOR A SUPPLIER?
